A daily regimen of risedronate was found to have superior efficacy to that of intermittent cyclical etidronate in increasing bone mineral density (BMD) among a cohort of Japanese patients with involutional osteoporosis.
Clinicians enrolled 235 patients with involutional osteoporosis in a multi-centre, randomized, double-masked, active (etidronate) controlled comparative trial. The clinical benefit of 2.5 mg daily risedronate and its effects on BMD of the lumbar spine was compared with etidronate, a representative of the bisphosphonates currently marketed in Japan. The patients were randomized to receive either 2.5 mg/day of risedronate for 48 weeks, or intermittent treatment with etidronate in four cycles of two weeks treatment with 200 mg/day, followed by 10 week medication-free periods.
Both treatment groups were given daily 200 mg calcium supplement in the form of the calcium lactate. Bone mineral density of the lumbar spine (L2-L4 BMD) was determined at 12, 24, 36 and 48 weeks by dual-energy X-ray absorptiometry.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!